Incorporated in 1998 and listed on the NSE/BSE in May 2024, Indegene Limited is a digital-first, end-to-end healthcare and technology company headquartered in Bengaluru. The company serves biopharmaceutical, emerging biotech, and medical device companies globally, helping them develop, commercialise, and manage products across the entire product lifecycle.

The company’s offering spans four broad solution pillars: Commercial Solutions (medical content, digital marketing, omnichannel engagement for HCPs and patients), Medical, Regulatory & Safety (MRS) (medical writing, pharmacovigilance, regulatory submissions), Data & Analytics, and an increasingly important Technology Platform layer powered by its proprietary BiologX and INDEGENE360 platforms.

Indegene’s addressable universe is the ~$30 billion global life sciences services market. Its key differentiator is the rare combination of deep domain expertise in healthcare with technology scalability — a moat that pure-play IT services or CROs struggle to replicate. Its client roster includes 18 of the top-20 global biopharma companies, providing strong revenue visibility and low client concentration risk at scale.

The company went public at ₹452/share in May 2024 and has been volatile since, impacted by margin headwinds, large PE-backed stake sales, and broader small-cap underperformance. The current price of ~₹452 represents a compelling re-entry near IPO price after the stock peaked at ₹736 in mid-2024.

Q3 FY26 Snapshot: Revenue surged 30.8% YoY to ₹942 Cr (a record quarter), driven by large MRS deal ramp-ups and acquisitions of BioPharm Communications and Warn & Co. However, net profit dipped 6.2% YoY to ₹102.9 Cr, reflecting integration costs and higher depreciation from M&A. Adjusted EBITDA grew 15.7% YoY to ₹174.7 Cr at a margin of ~18.5%.

The company remains nearly debt-free (borrowings down from ₹490 Cr in FY24 to ₹102 Cr in FY25), with reserves expanding to ₹2,568 Cr. This gives meaningful balance sheet headroom for further acquisitions or capital returns.

Revenue Growth Engine: Indegene reported its first-ever quarter exceeding ₹100M (USD) in revenue in Q1 FY26. Management has guided for sustained 20%+ organic growth, further boosted by acquisitions of BioPharm Communications (Canada) and Warn & Co (Europe), expanding its global MRS footprint. Analysts expect FY26 revenue of ~₹3,500–3,600 Cr (+20.7% YoY per Trendlyne consensus).

AI Integration — the growth wildcard: Indegene is aggressively embedding generative AI into its content, regulatory, and pharmacovigilance workflows. Management highlighted AI-driven productivity gains in the Q3 FY26 earnings call. This could either expand margins by reducing headcount per engagement, or be passed on to clients as pricing competitiveness — both scenarios being long-term positives.

EPS Trajectory: With consensus EPS of ₹21–24 for FY27 and ~30% profit growth CAGR over the last 3 years, EPS growth of 12–15% is the conservative path. At 25x P/E on ₹24 EPS (FY27E), fair value arrives at ₹600. At 28x on the bull case EPS of ₹28, target is ₹784.

Dividend policy: Indegene initiated its maiden dividend of ₹2/share in FY25 (12% payout). This is likely to grow modestly, but given strong reinvestment opportunities through M&A, do not expect high dividend yields in the near term.

Indegene trades at a 24.8x P/E — a meaningful discount to peers like Syngene (30x) and Metropolis (38x), despite delivering superior revenue CAGR of 19% over 3 years. The valuation discount is partly justified by the lack of a promoter holding and near-term margin compression, but represents an opportunity as those headwinds resolve. On an EV/EBITDA basis, Indegene trades at approximately 18–20x, reasonable for a 20%+ growth business with improving cash conversion.